DRIVE2Simplify Exploratory Analysis: Metabolic Outcomes With Islatravir Plus DOR vs DOR/3TC/TDF in ART-Naive Adults at Wk 48

March 8-11, 2020; Boston, Massachusetts
Changes in weight, body fat, BMD, and fasting lipid parameters were comparable among varying doses of islatravir + DOR vs DOR/3TC/TDF at Week 48 in ART-naive patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 215 KB
Released: March 14, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Clinical Care Options (CCO): woman’s perspective on her struggle with HIV stigma and why volunteering to help others with HIV has become her purpose

person default Anonymous Patient Released: January 10, 2022

From Dr. Fidelia Bernice and Clinical Care Options (CCO), expert commentary on managing polypharmacy in people with HIV

Fidelia Bernice, PharmD Released: January 6, 2022

Dr John Baxter and Clinical Care Options (CCO): Transmitted drug resistance does not necessarily preclude the use of many first line ART options.

John D. Baxter, MD Released: January 5, 2022

Expert faculty discuss guideline recommendations for individualizing ART, from Clinical Care Options (CCO)

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD
Program Director
Jean-Michel Molina, MD, PhD Cristina Mussini, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 29, 2021 Expired: December 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings